However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Under the terms of the agreement, Sanofi will provide data related to the unnamed drug compound, which is being considered for out-licensing, and Healx will use Healnet, its AI-driven drug discovery ...

In November 2021, Sanofi made a similar – but not its first – investment in AI, taking a $180 million equity stake in Franco-US start-up Owkin with another $90 million in funding for a ...

Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for clinical ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

“The future in this space is limitless,” said Frenehard. How AI is Enhancing Research and Development at Sanofi AI is being used across the value chain at Sanofi to get treatments to patients ...

SandboxAQ's Quantitative AI models aim to understand human biology ... The application with Sanofi focused on biomarker identification is very exciting as it increases our reach into later ...